Renal Effects of Bunazosin, a New αl-Adrenoceptor Blocker, in Patientswith Mild-to-Moderate Essential Hypertension
| Autor: | Tsuneharu Baba, T. Tomiyama, Kazuo Takebe, S. Murabayashi |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Pharmacology
medicine.medical_specialty Bunazosin Kidney Fractional excretion of sodium business.industry Renal function Propranolol Essential hypertension medicine.disease Endocrinology Blood pressure medicine.anatomical_structure Internal medicine Renal blood flow Medicine Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 15:826-830 |
| ISSN: | 0160-2446 |
| DOI: | 10.1097/00005344-199005000-00019 |
| Popis: | Renal effects of 4-week fixed maintenance doses of bunazosin three times daily (2.0 mg t.i.d., n = 8) and propranolol (40 mg t.i.d., n = 8) were evaluated in patients with mild-to-moderate essential hypertension [World Health Organization (WHO) stages I and II]. Both bunazosin and propranolol decreased blood pressure (BP) significantly (p less than 0.05), but the magnitude of reduction in diastolic BP (DBP) was greater with bunazosin (p less than 0.05) than with propranolol. Bunazosin produced a nonsignificant increase in renal blood flow (RBF) by 14%, a significant increase in glomerular filtration rate (GFR) 11% (p less than 0.05), and a decrease in total renal vascular resistance (TRR) by 15% (p less than 0.05), whereas propranolol caused no significant changes in these parameters. Urinary sodium excretion rate and the fractional excretion of sodium were unchanged by either of the drugs. The results of this short-term study suggest that bunazosin may be a drug that will increase RBF and GFR and decrease TRR with a concomitant hypotensive action in patients with mild-to-moderate essential hypertension. Whether these renal functional effects of the drug would benefit such patients must be determined in long-term studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|